{"entity":{"id":"idea-bio2-shared-compound-access-pool","kind":"idea","name":"A shared compound library that rare cancer researchers can actually use","aka":[],"tldr":"Companies hold thousands of well-characterised drugs that could help rare cancers, but each request takes a year of legal negotiation. One standing agreement would unblock it.","summary":"Academic rare cancer groups routinely fail to obtain clinical-grade compound for investigator-initiated trials because material transfer and intellectual property negotiation exceed the capacity of small teams. A pre-negotiated multi-company access pool (standard terms, a single application route, an independent scientific review committee and mandatory data return) would industrialise access. Precedents exist in structural genomics consortia and in some public-private compound-sharing schemes.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Rare and paediatric cancers without markets): Gatta et al., Rare cancers are not so rare: the rare cancer burden in Europe (EJC 2011)","url":"https://doi.org/10.1016/j.ejca.2011.08.008"}],"tags":[],"related":["drugbank-chembl","clinicaltrials-gov"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci","esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-rare-cancers","b-ip-collaboration","b-translational-valley"],"keyPapers":["paper-gatta-eur-j-cancer"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A standing access pool with standard terms reduces median time from request to compound receipt from over 12 months to under 3, and increases investigator-initiated rare cancer trials measurably within three years.","rationale":"Open science consortia have shown that pre-agreed standard terms remove the dominant transaction cost in cross-institution collaboration. Companies gain rare-indication data at almost no cost and retain their commercial position.","test":"Recruit five companies and 20 compounds into a pilot pool, then publish the median time to access and the number of trials initiated in the first two years.","maturity":"speculative","actor":"industry","cost":"medium","horizonYears":5},"route":"/ideas/idea-bio2-shared-compound-access-pool/","neighbours":{"collection":[{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/"},{"id":"drugbank-chembl","kind":"collection","name":"DrugBank & ChEMBL","route":"/collections/drugbank-chembl/"}],"institution":[{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"paper":[{"id":"paper-gatta-eur-j-cancer","kind":"paper","name":"Rare cancers are not so rare: the rare cancer burden in Europe","route":"/key-papers/paper-gatta-eur-j-cancer/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}